Table 2.
Baseline and clinical characteristics of the research subjects.
| Variable |
Cases (number = 120) |
Controls (number = 120) |
p-value |
|---|---|---|---|
| Age, mean (year) | 40.6 ± 12.9 | 38.4 ± 11.1 | 0.163 |
| Gender | |||
| - Females | 61 (50.8%) | 54 (45%) | 0.438 |
| - Males | 59 (49.2%) | 66 (55%) | |
| Smoking | |||
| - Non-Smoker | 78 (65.0 %) | 76 (63.3%) | 0.79 |
| - Smoker | 42 (35.0%) | 44 (36.7%) | |
| BMI | 26.55 ± 4.65 | 27.78 ± 4.03 | 0.112 |
| Obesity | |||
| - Non-obese | 80 (66.7%) | 90 (75%) | 0.201 |
| - Obese | 40 (33.3%) | 30 (25%) | |
| Age of onset | 34.35 ± 14.05 | ||
| - vEOP | 30 (25.0%) | ||
| - mEOP | 44 (36.7%) | ||
| - LOP | 46 (38.3%) | ||
| Severity of disease | |||
| - Mild | 51(42.5%) | ||
| - Moderate | 42 (35%) | ||
| - Severe | 27 (22.5%) | ||
| Duration of disease | 6.40 ± 6.55 | ||
| Family history | |||
| - Positive | 22 (18.3%) | ||
| - Negative | 98 (81.7) | ||
| Treatment | |||
| - No treatment | 42 (35.0%) | ||
| - On treatment | 78 (65.0%) | ||
| PASI | 13.43 ± 8.66 | ||
Data are presented as mean ± SD or number (percentage). p-values below 0.05 were deemed statistically significant. BMI, Body Mass Index; vEOP, Very early-onset psoriasis; mEOP, Middle-early onset psoriasis; LOP, Late-onset psoriasis; PASI, Psoriasis Area Severity Index.